Trial Information

Summary: Clinical trial to test an investigational study drug in moderate to severe chronic plaque psoriasis.

This research study is to evaluate the safety (side effects) of two different doses of an investigational study drug versus a placebo (a substance with no active medication) in people who have moderate to severe chronic plaque psoriasis.

Study drug and study procedures will be made available to you at no cost.

To qualify, you must:

  • Between the ages of 18 to 70 years old

You will not qualify if you:

  • Are a woman of child bearing potential
  • Have a live vaccination within 30 days of joining study
  • Have TB (tuberculosis)
  • Have participated in a research study within the past 30 days.

Research being conducted by:

Bruce Strober, MD

Contact:

Research Coordinator: Elizabeth Camacho
Biomedical Research Alliance of New York
NYU School of Medicine
Department of Dermatology
560 First Ave. - H - 158
New York, NY 10016
Telephone: 212-263-5244
Email:

Profile Page: Biomedical Research Alliance of New York, New York, NY

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:


Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:32:47 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA